AProgen doubles production capacity with addition of two new perfusion production lines

Pulse News reported that AProgen had doubled its production capacity with the addition of two new perfusion production lines, increasing total output capacity to 240,000 litres of culture fluid per cycle. AProgen currently has adalimumab, infliximab, trastuzumab, etanercept, cetuximab and bevacizumab biosimilars under development.